Guest Julian F, Davie Alison M, Ruiz Francis J, Greener Mark J
Catalyst Health Economics Consultants, 34b High Street, Northwood, Middlesex HA6 1BN, UK.
Prim Care Respir J. 2005 Apr;14(2):88-98. doi: 10.1016/j.pcrj.2005.01.002. Epub 2005 Feb 24.
To determine the costs and consequences of switching asthma patients, managed in primary care, from a twice-daily inhaled corticosteroid (ICS), to either a once-daily or another twice-daily ICS.
This was a case-control study based on an interrogation of the General Practice Research Database in the UK, for patients with a Read code of asthma who were managed between 1990 and 2001, and who had received at least two prescriptions for a twice-daily ICS within 12 months, before switching to a once-daily ICS (cases) or another twice-daily ICS (controls). Data on resource use was collected for one year before and after the switch. Patients were stratified according to whether their treatment step had been stepped up, stepped down or remained unchanged.
A modelling study performed from the perspective of the UK's National Health Service (NHS).
Compliance with ICS, and the cost of drug and non-drug resource use, for the year before and after the switch.
Switching patients managed in primary care to a once-daily ICS increased compliance and reduced NHS costs, irrespective of whether patients' treatment had been stepped up or down. Switching patients to another twice-daily ICS increased compliance to a lesser extent, and increased NHS costs. We believe that this paper offers the first documented association between compliance in asthma and NHS management costs.
Compliance and management costs among patients with asthma managed in primary care appear to be related to both changing treatment and dosing regimen. Within the limitations of our study, the results suggest that patients who are switched to a once-daily ICS rather than another twice-daily preparation are better compliers with their ICS medication. Additionally, patients who become high-compliers after being switched to a once-daily ICS incur lower management costs than patients who become high-compliers after being switched to another twice-daily ICS. These findings should now be investigated further under more controlled conditions.
确定在初级保健机构接受治疗的哮喘患者,从每日两次吸入性糖皮质激素(ICS)转换为每日一次或另一种每日两次ICS的成本和后果。
这是一项病例对照研究,基于对英国全科医学研究数据库的查询,研究对象为1990年至2001年间接受治疗且有哮喘Read编码的患者,这些患者在转换为每日一次ICS(病例组)或另一种每日两次ICS(对照组)之前的12个月内至少接受过两份每日两次ICS的处方。在转换前后一年收集资源使用数据。患者根据其治疗步骤是升级、降级还是保持不变进行分层。
从英国国家医疗服务体系(NHS)的角度进行的建模研究。
转换前后一年的ICS依从性以及药物和非药物资源使用成本。
将初级保健机构管理的患者转换为每日一次ICS可提高依从性并降低NHS成本,无论患者的治疗是升级还是降级。将患者转换为另一种每日两次ICS在较小程度上提高了依从性,但增加了NHS成本。我们认为本文首次记录了哮喘依从性与NHS管理成本之间的关联。
初级保健机构管理的哮喘患者的依从性和管理成本似乎与治疗和给药方案的改变有关。在我们研究的局限性内,结果表明,转换为每日一次ICS而非另一种每日两次制剂的患者对ICS药物的依从性更好。此外,转换为每日一次ICS后成为高依从性的患者比转换为另一种每日两次ICS后成为高依从性的患者产生的管理成本更低。这些发现现在应在更可控的条件下进一步调查。